These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35581099)

  • 21. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
    Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
    Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
    J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High genomic-based predicted strain coverage among invasive meningococcal isolates when combining Bexsero and Trumenba vaccines.
    Säll O; Olofsson E; Jacobsson S
    Vaccine; 2020 Jun; 38(28):4374-4378. PubMed ID: 32414653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.
    Mbaeyi SA; Bozio CH; Duffy J; Rubin LG; Hariri S; Stephens DS; MacNeil JR
    MMWR Recomm Rep; 2020 Sep; 69(9):1-41. PubMed ID: 33417592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical analysis of serogroup B meningococcal disease burden in Brazil (2001-2015): implications for public health decisions.
    Chicuto LAD; de Moraes C; Cássio de Moraes J; Sáfadi MAP
    Hum Vaccin Immunother; 2020 Aug; 16(8):1945-1950. PubMed ID: 31951784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens.
    Basta NE; Becker AB; Li Q; Nederhoff D
    Vaccine; 2019 Jan; 37(4):670-676. PubMed ID: 30587431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.
    Soeters HM; Whaley M; Alexander-Scott N; Kanadanian KV; MacNeil JR; Martin SW; McNamara LA; Sicard K; Vanner C; Vuong J; Wang X; Bandy U; Patel M;
    Clin Infect Dis; 2017 Apr; 64(8):1115-1122. PubMed ID: 28158417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
    Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
    Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations.
    Huang L; Goren A; Lee LK; Li VW; Dempsey A; Srivastava A
    Hum Vaccin Immunother; 2020 Apr; 16(4):933-944. PubMed ID: 31634035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcal B vaccination coverage among older adolescents in the United States.
    La EM; Garbinsky D; Hunter S; Poston S; Novy P; Ghaswalla P
    Vaccine; 2021 May; 39(19):2660-2667. PubMed ID: 33849722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
    Østergaard L; Vesikari T; Senders SD; Flodmark CE; Kosina P; Jiang HQ; Maguire JD; Absalon J; Jansen KU; Harris SL; Maansson R; Balmer P; Beeslaar J; Perez JL
    Vaccine; 2021 Jul; 39(32):4545-4554. PubMed ID: 34215452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
    Shirley M; Taha MK
    Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.
    McNamara LA; Shumate AM; Johnsen P; MacNeil JR; Patel M; Bhavsar T; Cohn AC; Dinitz-Sklar J; Duffy J; Finnie J; Garon D; Hary R; Hu F; Kamiya H; Kim HJ; Kolligian J; Neglia J; Oakley J; Wagner J; Wagner K; Wang X; Yu Y; Montana B; Tan C; Izzo R; Clark TA
    Pediatrics; 2015 May; 135(5):798-804. PubMed ID: 25917990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
    Tzanakaki G; Xirogianni A; Tsitsika A; Clark SA; Kesanopoulos K; Bratcher HB; Papandreou A; Rodrigues CMC; Maiden MCJ; Borrow R; Tsolia M
    Vaccine; 2021 Mar; 39(11):1621-1630. PubMed ID: 33597116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.
    Marjuki H; Chang HY; Topaz N; Whaley MJ; Vuong J; Chen A; Jenkins LT; Hu F; Schmink S; Retchless AC; Thomas JD; Acosta AM; McNamara LA; Soeters HM; Mbaeyi S; Wang X
    mBio; 2021 May; 12(3):. PubMed ID: 34006659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018.
    Soeters HM; McNamara LA; Blain AE; Whaley M; MacNeil JR; Hariri S; Mbaeyi SA;
    Emerg Infect Dis; 2019 Mar; 25(3):434-440. PubMed ID: 30789140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.